R2M Pharma is a collaborative pharmaceutical company that works with you as partners throughout the discovery and development phase
Founder & Chief Executive Officer
Julio Medina, Ph.D.
“R2M Pharma was established in early 2017. Our mission is to produce high quality drug candidates, in a cost effective and timely manner. We aim at accelerating drug discovery by leveraging an experienced group of skilled scientists and strategic partners with a proven track record of delivering high quality drug candidates. Our goal is to create value for our partners by accelerating the discovery of quality development molecules for evaluation in clinical trials aimed at discovering new drugs for patients in need."
- Julio Medina, Founder & CEO
Dr. Medina has over 28 years of experience in drug discovery and development. Prior to joining R2M, he worked at ORIC Pharmaceuticals as the Vice President of Drug Discovery and at Amgen as an Executive Director of Research where he was responsible for leading the Medicinal Chemistry group in South San Francisco. Previously, he held the position of Director of Chemistry at Tularik. Dr. Medina has successfully led programs on protein-protein interactions, kinases, GPCR agonists and antagonists, nuclear receptors and enzymatic targets to identify 9 clinical development compounds in oncology, immunology and metabolic disease therapeutic areas. He is a co-author on 83 publications and a co-inventor on 50 issued and pending patents. He did his post-doctoral studies at Columbia University and received his Ph.D. at the University of Miami.